TY - JOUR
T1 - A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition
AU - Mcinnes, Iain B.
AU - Szekanecz, Zoltán
AU - Mcgonagle, Dennis
AU - Maksymowych, Walter P.
AU - Pfeil, Alexander
AU - Lippe, Ralph
AU - Song, In Ho
AU - Lertratanakul, Apinya
AU - Sornasse, Thierry
AU - Biljan, Ana
AU - Deodhar, Atul
N1 - Publisher Copyright:
© The Author(s) 2021.
PY - 2022/5/1
Y1 - 2022/5/1
N2 - Spondyloarthritis (SpA) comprises a group of chronic inflammatory diseases with overlapping clinical, genetic and pathophysiological features including back pain, peripheral arthritis, psoriasis, enthesitis and dactylitis. Several cytokines are involved in the pathogenesis of SpA, variously contributing to each clinical manifestation. Many SpA-associated cytokines, including IL-23, IL-17, IL-6, type I/II interferon and tumour necrosis factor signal directly or indirectly via the Janus kinase (JAK)-signal transducer and activator of transcription pathway. JAK signalling also regulates development and maturation of cells of the innate and adaptive immune systems. Accordingly, disruption of this signalling pathway by small molecule oral JAK inhibitors can inhibit signalling implicated in SpA pathogenesis. Herein we discuss the role of JAK signalling in the pathogenesis of SpA and summarize the safety and efficacy of JAK inhibition by reference to relevant SpA clinical trials.
AB - Spondyloarthritis (SpA) comprises a group of chronic inflammatory diseases with overlapping clinical, genetic and pathophysiological features including back pain, peripheral arthritis, psoriasis, enthesitis and dactylitis. Several cytokines are involved in the pathogenesis of SpA, variously contributing to each clinical manifestation. Many SpA-associated cytokines, including IL-23, IL-17, IL-6, type I/II interferon and tumour necrosis factor signal directly or indirectly via the Janus kinase (JAK)-signal transducer and activator of transcription pathway. JAK signalling also regulates development and maturation of cells of the innate and adaptive immune systems. Accordingly, disruption of this signalling pathway by small molecule oral JAK inhibitors can inhibit signalling implicated in SpA pathogenesis. Herein we discuss the role of JAK signalling in the pathogenesis of SpA and summarize the safety and efficacy of JAK inhibition by reference to relevant SpA clinical trials.
KW - AS
KW - Janus kinase inhibitor
KW - PsA
KW - spondyloarthritis
UR - http://www.scopus.com/inward/record.url?scp=85129997553&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129997553&partnerID=8YFLogxK
U2 - 10.1093/rheumatology/keab740
DO - 10.1093/rheumatology/keab740
M3 - Article
C2 - 34668515
AN - SCOPUS:85129997553
SN - 1462-0324
VL - 61
SP - 1783
EP - 1794
JO - Rheumatology (United Kingdom)
JF - Rheumatology (United Kingdom)
IS - 5
ER -